Key Record Dates
| ClinicalTrials.gov Identifier: | NCT01855750 |
|---|---|
| Brief Title: | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma |
| First Submitted : | May 14, 2013 |
| First Submitted that Met QC Criteria : | May 14, 2013 |
| First Posted : | May 16, 2013 (Estimate) |
| Results First Submitted : | February 22, 2019 |
| Results First Submitted that Met QC Criteria : | February 22, 2019 |
| Results First Posted : | March 19, 2019 |
| Last Update Submitted that Met QC Criteria : | March 30, 2020 |
| Last Update Posted : | April 13, 2020 |